Insulin resistance, a key factor in the pathogenesis of type 2 diaebtes, is a heterogeneous disorder caused by a range of genetic and environmental factors. This heterogeneity provides significant challenges to the development of effective therapeutic regimes for long-term management of type 2 diabetes. Weu sed a novel strategy to identify a gene expression signature (GES) that reflects the overall state of insulin resistance in both cells and patients. The advantage of GESs is that theyare the minimal set of genes that represent the integrated biological response of a cell/tissue to its environment. The insulin resistance GES was developed in 3T3-L1 adipocytes that were made 'insulin resistant' by treatment with the pro-inflammatory cytokine TNFα± and then reversed with a salicylate and a thiazolidinedione ('re-sensitized'). The GES consisted of fiveg enes whose expression levels best discriminated between the insulin resistant and insulin re-sensitized states. The biological relevance of the cell culture-derivedG ES was assessed by determining relationships between expression levels of the GES genes and metabolic syndrome phenotypes in patients, where we identified individuals with a higher degree of insulin resistance based on their GES expression profile (P <0.001).
